Variable dictionary for Canadian Cancer Trials Group MA.17R

Note: Blank cell means the entry does not apply to the variable. For example, OS type will be blank when the patients was alive. In some variables, 'U' is coded for 'unknown'.

Variable name	Variable	Note
cctg_nci_id	Pseudo CCTG MA17R ID	A pseudo ID with one-to-one mapping to original CCTG patient ID. Format MA17R_0001 to MA17R_1918.
age	Age	In years (age in days/365.25)
eligible	Eligible	Y: Yes N: No
number_mpv	Number of major protocol violation	0,1,2
diagdur	Time from first diagnosis of breast cancer to randomization	In years
tstage	Tumor stage at diagnosis	1:T1; 2:T2; 3:T3; 4:T4; X:TX
nstage	Nodal stage of disease at diagnosis	0:N0; 1:N1; 2:N2; 3:N3; X:NX
repstatus	Hormone-receptor status: estrogen, progesterone, or both	P: positive N: negative M: missing U: unknown
tamox_dur	Duration of tamoxifen therapy	In years
aitdur	Duration of previous aromatase-inhibitor therapy	In years
recurrence	Recurrence of the primary cancer or with contralateral breast cancer	Y: Yes N: No
breast_local	Local breast recurrence	Y: Yes N: No
chest_local	Local chest wall recurrence	Y: Yes N: No
regional	Regional recurrence	Y: Yes N: No
distant	Distant recurrence	Y: Yes N: No
asc	Site of distant recurrence: Ascites	Y: Yes N: No
bon	Site of distant recurrence: Bone	Y: Yes N: No
bra	Site of distant recurrence: Brain	Y: Yes N: No
liv	Site of distant recurrence: Liver	Y: Yes N: No
lun	Site of distant recurrence: Lung	Y: Yes N: No
mar	Site of distant recurrence: Bone marrow	Y: Yes N: No
ome	Site of distant recurrence: Omentum	Y: Yes N: No
per	Site of distant recurrence: Peritoneum	Y: Yes N: No
pff	Site of distant recurrence: Pleural effusion	Y: Yes N: No
ple	Site of distant recurrence: Pleura	Y: Yes N: No
oth	Site of distant recurrence: Other	Y: Yes N: No
contralateral	Contralateral breast cancer	Y: Yes N: No
ittarm	Treatment group (ITT): allocated at time of randomization for all women randomized (for baseline characteristics and efficacy analyses)	A: Letrozole, B: Placebo
trtarm	Treatment group (treated): according to treatment women actually received for all women who received at least one dose of protocol treatment (for treatment exposure and safety analyses)	A: Letrozole, B: Placebo
time_dfs	Disease-free survival time	in years (days / 365.25)
event_dfs	Disease-free survival event	0 for censoring; 1 for event
time_os	Overall survival time	in years (days / 365.25)
event_os	Overall survival event	0 for censoring; 1 for event
time_dfssen	Disease-free survival time (sensitivity analysis)	in years (days / 365.25)
event_dfssen	Disease-free survival event (sensitivity analysis)	0 for censoring; 1 for event
time_contr	Time to the development of contralateral breast cancer	in years (days / 365.25)
event_contr	Contralateral breast cancer event	0 for censoring;1 for event
cdede	Toxic effect during treatment: Edema	Y: Yes N: No. blank for patients not treated
cdhbp	Toxic effect during treatment: Hypertension	Y: Yes N: No. blank for patients not treated
enfla	Toxic effect during treatment: Hot flashes	Y: Yes N: No. blank for patients not treated
fllet	Toxic effect during treatment: Fatigue	Y: Yes N: No. blank for patients not treated
gicon	Toxic effect during treatment: Constipation	Y: Yes N: No. blank for patients not treated
gidia	Toxic effect during treatment: Diarrhea	Y: Yes N: No. blank for patients not treated
msjoi	Toxic effect during treatment: Arthritis	Y: Yes N: No. blank for patients not treated
mthch	Toxic effect during treatment: Hypercholesterolemia	Y: Yes N: No. blank for patients not treated
nediz	Toxic effect during treatment: Dizziness	Y: Yes N: No. blank for patients not treated
paihe	Toxic effect during treatment: Headache	Y: Yes N: No. blank for patients not treated
neins	Toxic effect during treatment: Insomnia	Y: Yes N: No. blank for patients not treated
paijo	Toxic effect during treatment: Arthralgia	Y: Yes N: No. blank for patients not treated
paimy	Toxic effect during treatment: Myalgia	Y: Yes N: No. blank for patients not treated
paios	Toxic effect during treatment: Bone pain	Y: Yes N: No. blank for patients not treated
pusob	Toxic effect during treatment: Dyspnea	Y: Yes N: No. blank for patients not treated
sxdry	Toxic effect during treatment: Vaginal dryness	Y: Yes N: No. blank for patients not treated

alkph	Elevated alkaline phosphatase level during treatment	Y: Yes N: No. blank for patients not treated or not evaluated
alt	Elevated alanine aminotransferase level during treatment	Y: Yes N: No. blank for patients not treated or not evaluated
ast	Elevated aspartate aminotransferase level during treatment	Y: Yes N: No. blank for patients not treated or not evaluated
any_frac_ontrt	Bone fracture during treatment	Y: Yes N: No. blank for patients not treated
spine_ontrt	Bone fracture during treatment: Spine	Y: Yes N: No. blank for patients not treated
wrist_ontrt	Bone fracture during treatment: Wrist	Y: Yes N: No. blank for patients not treated
pelvis_ontrt	Bone fracture during treatment: Pelvis	Y: Yes N: No. blank for patients not treated
hip_ontrt	Bone fracture during treatment: Hip	Y: Yes N: No. blank for patients not treated
femur_ontrt	Bone fracture during treatment: Femur	Y: Yes N: No. blank for patients not treated
tibia_ontrt	Bone fracture during treatment: Tibia	Y: Yes N: No. blank for patients not treated
ankle_ontrt	Bone fracture during treatment: Ankle	Y: Yes N: No. blank for patients not treated
other_ontrt	Bone fracture during treatment: Other	Y: Yes N: No. blank for patients not treated
ontrt_osteo	New-onset osteoporosis during treatment	Y: Yes N: No. blank for patients not treated
any_card	Cardiovascular event during treatment	Y: Yes N: No. blank for patients not treated
enfla_off	Toxic effect after treatment: Hot flashes	Y: Yes N: No. blank for patients not treated
paijo_off	Toxic effect after treatment: Arthralgia	Y: Yes N: No. blank for patients not treated
cdhbp_off	Toxic effect after treatment: Hypertension	Y: Yes N: No. blank for patients not treated
cdsvt_off	Toxic effect after treatment: Superventricular arrhythmia	Y: Yes N: No. blank for patients not treated
any_frac_offtrt	Bone fracture after treatment	Y: Yes N: No. blank for patients not treated
spine_offtrt	Bone fracture after treatment: Spine	Y: Yes N: No. blank for patients not treated
wrist_offtrt	Bone fracture after treatment: Wrist	Y: Yes N: No. blank for patients not treated
pelvis_offtrt	Bone fracture after treatment: Pelvis	Y: Yes N: No. blank for patients not treated
hip_offtrt	Bone fracture after treatment: Hip	Y: Yes N: No. blank for patients not treated
femur_offtrt	Bone fracture after treatment: Femur	Y: Yes N: No. blank for patients not treated
tibia_offtrt	Bone fracture after treatment: Tibia	Y: Yes N: No. blank for patients not treated
ankle_offtrt	Bone fracture after treatment: Ankle	Y: Yes N: No. blank for patients not treated
other_offtrt	Bone fracture after treatment: Other	Y: Yes N: No. blank for patients not treated
offtrt_osteo	New-onset osteoporosis after treatment	Y: Yes N: No. blank for patients not treated
adhere	Adherence to the study regimen	Y: Yes N: No
ai_break	Continuous breaks of longer than 6 months in treatment with aromatase inhibitor	Y: Yes N: No
ai_to_rand	Interval between the last dose of aromatase inhibitor and randomization	in years (days / 365.25), . for patients without any dose of aromatase inhibitor.
trt_duration	duration of the study regimen	in years (days / 365.25), . for patients not treated
str_node_desc	Stratification factor : Node status at diagnosis	Negative; Positive; Unknown
str_pc_desc	Stratification factor :Prior adjuvant chemotherapy	No; Yes
str_ai_desc	Stratification factor :Interval between last dose of aromatase inhibitor therapy and randomization	<= 6 months; 6 months to 2 years
str_tam_desc	Stratification factor : Duration of prior tamoxifen use	0; < 2 years; 2-4.5 years; > 4.5 years
cause_of_death	Cause of death	Blank for patients who were still at alive at time of analysis
offrea	Reasons off study regimen	blank for patients not treated
chgp_hip_dexa_opt	Percentage Change of BMD in the total hip at the time off treatment from baseline	. for patients without BMD in the total hip at baseline or time off treatment
chgp_spn_dexa_opt	Percentage Change of BMD in the lumbar spine at the time off treatment from baseline	. for patients without BMD in the lumber spine at baseline or time off treatment
spnt	Lumbar spine T score <-2.5 at any time after the baseline	Y: Yes N: No. blank for patients without T score at the lumbar spine data at any time after baseline
bisphos	Use of bisphosphonates during treatment	Y: Yes N: No. blank for patients not treated
calcium	Use of calcium supplements during treatment	Y: Yes N: No. blank for patients not treated
vit_d	Use of vitamin D supplements during treatment	Y: Yes N: No. blank for patients not treated
serm	Use of selective estrogen-receptor modulator during treatment	Y: Yes N: No. blank for patients not treated
exp_bl	QOL expected at baseline	Y: Yes N: No
cmpl_bl	QOL assessed at baseline	Y: Yes N: No. blank for patients not expected at baseline
exp_m12	QOL expected at month 12	Y: Yes N: No
cmpl_m12	QOL assessed at month 12	Y: Yes N: No. blank for patients not expected at month 12
exp_m24	QOL expected at month 24	Y: Yes N: No
cmpl_m24	QOL assessed at month 24	Y: Yes N: No. blank for patients not expected at month 24
exp_m36	QOL expected at month 36	Y: Yes N: No
cmpl_m36	QOL assessed at month 36	Y: Yes N: No. blank for patients not expected

		at month 36
exp_m48	QOL expected at month 48	Y: Yes N: No
cmpl_m48	QOL assessed at month 48	Y: Yes N: No. blank for patients not expected at month 48
exp_m60	QOL expected at month 60	Y: Yes N: No
cmpl_m60	QOL assessed at month 60	Y: Yes N: No. blank for patients not expected at month 60
sf_rp_bl	SF-36 role–physical score at baseline	. for patients without assessment
sf_rp_m12	SF-36 role–physical score at month 12	. for patients without assessment
sf_rp_m24	SF-36 role–physical score at month 24	. for patients without assessment
sf_rp_m36	SF-36 role–physical score at month 36	. for patients without assessment
sf_rp_m48	SF-36 role–physical score at month 48	. for patients without assessment
sf_rp_m60	SF-36 role–physical score at month 60	. for patients without assessment
sf_bp_bl	SF-36 bodily pain score at baseline	. for patients without assessment
sf_bp_m12	SF-36 bodily pain score at month 12	. for patients without assessment
sf_bp_m24	SF-36 bodily pain score at month 24	. for patients without assessment
sf_bp_m36	SF-36 bodily pain score at month 36	. for patients without assessment
sf_bp_m48	SF-36 bodily pain score at month 48	. for patients without assessment
sf_bp_m60	SF-36 bodily pain score at month 60	. for patients without assessment
sf_re_bl	SF-36 role–emotional score at baseline	. for patients without assessment
sf_re_m12	SF-36 role–emotional score at month 12	. for patients without assessment
sf_re_m24	SF-36 role–emotional score at month 24	. for patients without assessment
sf_re_m36	SF-36 role–emotional score at month 36	. for patients without assessment
sf_re_m48	SF-36 role–emotional score at month 48	. for patients without assessment
sf_re_m60	SF-36 role–emotional score at month 60	. for patients without assessment
casec_sae	Worst grade of Serious Adverse Event: Secondary Malignancy	0, 1, 2, 3, 4, 5, . for patients not treated
cddys_sae	Worst grade of Serious Adverse Event: Ventricular arrhythmia	0, 1, 2, 3, 4, 5, . for patients not treated
cdede_sae	Worst grade of Serious Adverse Event: Edema	0, 1, 2, 3, 4, 5, . for patients not treated
cdfun_sae	Worst grade of Serious Adverse Event: Cardiac LVF	0, 1, 2, 3, 4, 5, . for patients not treated
cdisc_sae	Worst grade of Serious Adverse Event: Ischemia/infarction	0, 1, 2, 3, 4, 5, . for patients not treated
cdoth_sae	Worst grade of Serious Adverse Event: Cardiovascular - Other	0, 1, 2, 3, 4, 5, . for patients not treated
cdsvt_sae	Worst grade of Serious Adverse Event: Supraventricular arrhythmia	0, 1, 2, 3, 4, 5, . for patients not treated
cdtni_sae	Worst grade of Serious Adverse Event: Cardiac troponin I	0, 1, 2, 3, 4, 5, . for patients not treated
cdven_sae	Worst grade of Serious Adverse Event: Thrombosis/embolism	0, 1, 2, 3, 4, 5, . for patients not treated
fllet_sae	Worst grade of Serious Adverse Event: Fatigue	0, 1, 2, 3, 4, 5, . for patients not treated
floth_sae	Worst grade of Serious Adverse Event: Flu-Like Symptoms - Other	0, 1, 2, 3, 4, 5, . for patients not treated
gucre_sae	Worst grade of Serious Adverse Event: Creatinine	0, 1, 2, 3, 4, 5, . for patients not treated
gukid_sae	Worst grade of Serious Adverse Event: Renal failure	0, 1, 2, 3, 4, 5, . for patients not treated
hmcns_sae	Worst grade of Serious Adverse Event: CNS hemorrhage/bleeding	0, 1, 2, 3, 4, 5, . for patients not treated
hmcol_sae	Worst grade of Serious Adverse Event: Melena/GI bleeding	0, 1, 2, 3, 4, 5, . for patients not treated
hmrec_sae	Worst grade of Serious Adverse Event: Rectal bleeding	0, 1, 2, 3, 4, 5, . for patients not treated
hpcli_sae	Worst grade of Serious Adverse Event: Liver dysfunction	0, 1, 2, 3, 4, 5, . for patients not treated
hpoth_sae	Worst grade of Serious Adverse Event: Hepatic - Other	0, 1, 2, 3, 4, 5, . for patients not treated
infec_sae	Worst grade of Serious Adverse Event: Infection w/o neutropenia	0, 1, 2, 3, 4, 5, . for patients not treated
inunk_sae	Worst grade of Serious Adverse Event: Infection-unknown ANC	0, 1, 2, 3, 4, 5, . for patients not treated
neart_sae	Worst grade of Serious Adverse Event: CNS cerebrovascular ischemia	0, 1, 2, 3, 4, 5, . for patients not treated
nemot_sae	Worst grade of Serious Adverse Event: Neuropathy-motor	0, 1, 2, 3, 4, 5, . for patients not treated
ototh_sae	Worst grade of Serious Adverse Event: Other - Other	0, 1, 2, 3, 4, 5, . for patients not treated
pueff_sae	Worst grade of Serious Adverse Event: Pleural effusion	0, 1, 2, 3, 4, 5, . for patients not treated
pulox_sae	Worst grade of Serious Adverse Event: Hypoxia	0, 1, 2, 3, 4, 5, . for patients not treated
puoth_sae	Worst grade of Serious Adverse Event: Pulmonary - Other	0, 1, 2, 3, 4, 5, . for patients not treated
pupne_sae	Worst grade of Serious Adverse Event: Pneumonitis	0, 1, 2, 3, 4, 5, . for patients not treated
pusob_sae	Worst grade of Serious Adverse Event: Dyspnea	0, 1, 2, 3, 4, 5, . for patients not treated
race	Race/ethnicity	1: White (not of Hispanic origin) 2: Hispanic 3: Black (not of Hispanic origin) 4: Asian or Pacific Islander 6: Native North American or Native Alaskan 98: Other 99: Unknown(or refusal)
perf_sta	ECOG Performance Status	0, 1, 2

erstatus	Estrogen receptor status	P: positive N: negative M: missing U: unknown
prstatus	Progesterone receptor status	P: positive N: negative M: missing U: unknown
ai_let	Type of previous AI therapy: Letrozole	Y: Yes N: No
ai_ana	Type of previous AI therapy: Anastrozole	Y: Yes N: No
ai_exe	Type of previous AI therapy: Exemestane	Y: Yes N: No
any_chem	Prior adjuvant chemotherapy - baseline	Y: Yes N: No
surg_lnd	Prior surgery: Lymph Node Dissection	Y: Yes N: No
surg_lum	Prior surgery: Lumpectomy	Y: Yes N: No
surg_mas	Prior surgery: Mastectomy	Y: Yes N: No